RYZ811
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for RYZ811, covering 2026-04-13 to 2026-04-13. Get the full timeline:
Most recent: Clinical Trial Update: Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC [Phase 1, Phase 2]